August 2012
-
The FDA has accepted OptiNose’s new drug application for its OPN-375 intranasal fluticasone for the treatment of nasal polyposis in adult patients, with an anticipated PDUFA date in September 2017, the company announced. OptiNose CEO… Read more . . .
-
Q: What benefits are offered by extrafine particles? A: There is growing evidence to suggest that finer aerosols may enable us to effectively direct particles into more efficacious areas of the lung and to achieve a… Read more . . .
-
Bangladeshi generics company Beximco Pharmaceuticals announced that it has entered into a joint venture with Malaysian pharma company BioCare and said that the first joint project, an MDI manufacturing facility in Seri Iskandar Pharmaceutical Park,… Read more . . .
-
Inhaled drug developer Pulmatrix has announced an agreement to sell approximately 2 million shares of its common stock to institutional investors at $2.50 per share in a registered direct offering expected to generate net proceeds… Read more . . .
-
The FDA has approved the Symbicort budesonide/formoterol fumarate 80/4.5 μg MDI for the treatment of asthma in patients aged 6-12, AstraZeneca has announced. The company previously announced that it had received pediatric exclusivity for the… Read more . . .
-
According to Teva Pharmaceutical Industries, the FDA has approved 3 strengths each for the AirDuo RespiClick fluticasone propionate/salmeterol DPI and the ArmonAir RespiClick fluticasone propionate DPI for the treatment of asthma in patients aged 12… Read more . . .
-
OptiNose has announced that Keith A. Goldan has joined the company as Chief Financial Officer. Goldan was most recently Senior VP and CFO of Fibrocell and previously served as CFO at NuPathe, PuriCore (now Realm… Read more . . .
-
AstraZeneca has announced that the FDA had granted 6 months of pediatric exclusivity for its Symbicort budesonide/formoterol MDI based on trials in asthmatic children aged 6-12. In August 2016, AstraZeneca announced that its CHASE 3… Read more . . .
-
Adapt Pharma announced that it has received FDA approval for a 2 mg dose version of Narcan naloxone nasal spray for the treatment of opioid overdose for opioid-addicted patients who would likely experience severe withdrawal… Read more . . .
-
The International Society for Aerosols in Medicine (ISAM) has planned a number of activities for 2017 in line with its mission “to stimulate and further the interdisciplinary cooperation and exchange of information in all aspects… Read more . . .
Featured event:
5th Annual Inhaled & Nasal Biologics | DNA Forum
5th Annual Inhaled & Nasal Biologics | DNA Forum
24th-25th September 2026, Cambridge, UK
Join us for a ground-breaking and insightful forum: Two days of cutting-edge talks and networking opportunities in this complex area of drug and vaccine development.
With renowned industry leaders who will share their insights and real-world case studies, our speakers will explore innovative formulation and delivery technologies and the rationale behind overcoming development challenges. Don’t miss out on this opportunity to learn more about key topics shaping the future of inhaled therapeutics.
Get online to see speakers announced so far. Registration is live – save your seat now!
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden
October 21-October 22: MVIC Symposium, Lund, Sweden
November 10-November 11: Rescon Europe 2026, Porto, Portugal
December 9-December 11: DDL 2026, Edinburgh, Scotland